BioVentrix names interventional cardiologist Ryan A. Brown M.D. as vice president of medical affairs

Published
Thursday, March 26, 2015

BioVentrix,Inc. a pioneer of technologies and procedures

SAN RAMON, Calif., March 26, 2015 — BioVentrix,Inc. a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF), today announced the appointment of Dr. Ryan A. Brown, M.D., as the vice president of medical affairs. In his new role, Dr. Brown will provide medical and scientific leadership on the expansion of the less invasive ventricular enhancement (LIVETM) procedure for BioVentrix’s Revivent-TCTM Transcatheter Ventricular Enhancement System.

“Dr. Brown will leverage his interventional cardiology expertise and many years of patient care to enhance the clinical value of the life-saving products provided by BioVentrix,” said Kenneth Miller, president and chief executive officer of BioVentrix. “He will be an important part of our strategic growth as we continue to enhance our current product, Revivent-TCTM Transcatheter Ventricular Enhancement System, and will lead many efforts surrounding future developments. The addition of Dr. Brown shows our commitment to provide innovative solutions to treat patients suffering from ischemic cardiomyopathy.”

Dr. Brown remains a practicing interventional cardiologist at the Cardiovascular Consultants Medical Group, John Muir Cardiovascular Institute in Walnut Creek, California. He holds a doctorate of medicine from Northwestern University School of Medicine in Chicago, Illinois and is board certified in cardiology, internal medicine, interventional cardiology, and nuclear cardiology.

“I look forward to working with the team at Bioventrix and contributing to the development and expansion of current technologies that aim to improve outcomes in ischemic heart failure,” said Dr. Brown. “Heart failure solutions provided by BioVentrix serve as an important option for heart failure patients. With many valvular and vascular therapies available, the technology offers a much needed less-invasive ventricular therapy to add to the patient care continuum for those who can benefit from left ventricular restoration. In this role I will provide the scientific and medical leadership to develop innovative solutions for enhancing the care of heart failure patients.”

About the Revivent-TC System and the LIVE Procedure

Placement of the Revivent-TC System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled toward one another, effectively excluding the scarred and non-functioning heart wall. The efficiency of the remaining heart muscle is immediately improved, by as much as 30-40 percent.i Presentation of recent scientific data indicates that in 92 percent of patients, the efficacy results were durable beyond one year.ii

About BioVentrix

BioVentrix, a privately held medical technology company headquartered in San Ramon, Calif., is focused on developing and commercializing minimally invasive as well as nonsurgical therapies for treating HF.

Click here for corporate video with animation

NOTE: The Revivent-TCTM Transcatheter Ventricular Enhancement System requires regulatory approval and is not yet commercially available.

Contact: David Schickling, VP of Sales and Marketing, +1-925-830-1000


i Wechsler, A. et al, Clinical benefits twelve months after less invasive ventricular restoration operations without ventriculotomy. Annual meeting of the European Society of Cardio-Thoracic Surgery, 07 Oct. 2013, Vienna, Austria.

ii Ibid.